723 related articles for article (PubMed ID: 16890572)
21. Effect of long-term orlistat treatment on serum levels of advanced glycation end-products in women with polycystic ovary syndrome.
Diamanti-Kandarakis E; Katsikis I; Piperi C; Alexandraki K; Panidis D
Clin Endocrinol (Oxf); 2007 Jan; 66(1):103-9. PubMed ID: 17201808
[TBL] [Abstract][Full Text] [Related]
22. Metformin therapy increases insulin-like growth factor binding protein-1 in hyperinsulinemic women with polycystic ovary syndrome.
Pawelczyk L; Spaczynski RZ; Banaszewska B; Duleba AJ
Eur J Obstet Gynecol Reprod Biol; 2004 Apr; 113(2):209-13. PubMed ID: 15063962
[TBL] [Abstract][Full Text] [Related]
23. [Insulin release and daily glucose change in polycystic ovary syndrome women with normal glucose tolerance].
Tao MF; Zhu JP; Zhou J; Lu W; Qin W; Teng YC; Jia WP
Zhonghua Yi Xue Za Zhi; 2009 Mar; 89(10):659-63. PubMed ID: 19595057
[TBL] [Abstract][Full Text] [Related]
24. Effect of metformin administration on plasma advanced glycation end product levels in women with polycystic ovary syndrome.
Diamanti-Kandarakis E; Alexandraki K; Piperi C; Aessopos A; Paterakis T; Katsikis I; Panidis D
Metabolism; 2007 Jan; 56(1):129-34. PubMed ID: 17161235
[TBL] [Abstract][Full Text] [Related]
25. Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity.
Baillargeon JP; Jakubowicz DJ; Iuorno MJ; Jakubowicz S; Nestler JE
Fertil Steril; 2004 Oct; 82(4):893-902. PubMed ID: 15482765
[TBL] [Abstract][Full Text] [Related]
26. Clinical and endocrinological effects of 6 months of metformin treatment in young hyperinsulinemic patients affected by polycystic ovary syndrome.
Loverro G; Lorusso F; De Pergola G; Nicolardi V; Mei L; Selvaggi L
Gynecol Endocrinol; 2002 Jun; 16(3):217-24. PubMed ID: 12192894
[TBL] [Abstract][Full Text] [Related]
27. The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome.
Yilmaz M; Karakoç A; Törüner FB; Cakir N; Tiras B; Ayvaz G; Arslan M
Gynecol Endocrinol; 2005 Sep; 21(3):154-60. PubMed ID: 16335907
[TBL] [Abstract][Full Text] [Related]
28. Insulin response to oral glucose in healthy, lean young women and patients with polycystic ovary syndrome.
Kulshreshtha B; Ganie MA; Praveen EP; Gupta N; Lal Khurana M; Seith A; Dwivedi SN; Kumar G; Ammini AC
Gynecol Endocrinol; 2008 Nov; 24(11):637-43. PubMed ID: 19031221
[TBL] [Abstract][Full Text] [Related]
29. Increased levels of serum advanced glycation end-products in women with polycystic ovary syndrome.
Diamanti-Kandarakis E; Piperi C; Kalofoutis A; Creatsas G
Clin Endocrinol (Oxf); 2005 Jan; 62(1):37-43. PubMed ID: 15638868
[TBL] [Abstract][Full Text] [Related]
30. An observational study of reduction of insulin resistance and prevention of development of type 2 diabetes mellitus in women with polycystic ovary syndrome treated with metformin and diet.
Glueck CJ; Goldenberg N; Sieve L; Wang P
Metabolism; 2008 Jul; 57(7):954-60. PubMed ID: 18555837
[TBL] [Abstract][Full Text] [Related]
31. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
[TBL] [Abstract][Full Text] [Related]
32. Absence of profound hyperinsulinism in polycystic ovary syndrome is associated with subtle elevations in the plasminogen activator inhibitor system.
Sills ES; Drews CD; Perloe M; Tucker MJ; Kaplan CR; Palermo GD
Gynecol Endocrinol; 2003 Jun; 17(3):231-7. PubMed ID: 12857431
[TBL] [Abstract][Full Text] [Related]
33. Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance.
Sepilian V; Nagamani M
J Clin Endocrinol Metab; 2005 Jan; 90(1):60-5. PubMed ID: 15483106
[TBL] [Abstract][Full Text] [Related]
34. [Effect of long-term treatment with metformin on steroid levels and parameters of insulin resistance in women with polycystic ovary syndrome].
Vrbíková J; Hill M; Stárka L; Cibula D; Snajderová M; Sulcová J; Vondra K; Bendlová B
Cas Lek Cesk; 2001 Nov; 140(22):688-94. PubMed ID: 11789058
[TBL] [Abstract][Full Text] [Related]
35. Effects of metformin on clinical and biochemical parameters in polycystic ovary syndrome.
Kriplani A; Agarwal N
J Reprod Med; 2004 May; 49(5):361-7. PubMed ID: 15214709
[TBL] [Abstract][Full Text] [Related]
36. Hyperreninemia characterizing women with polycystic ovary syndrome improves after metformin therapy.
Diamanti-Kandarakis E; Economou FN; Livadas S; Tantalaki E; Piperi C; Papavassiliou AG; Panidis D
Kidney Blood Press Res; 2009; 32(1):24-31. PubMed ID: 19212122
[TBL] [Abstract][Full Text] [Related]
37. Serum total L-carnitine levels in non-obese women with polycystic ovary syndrome.
Fenkci SM; Fenkci V; Oztekin O; Rota S; Karagenc N
Hum Reprod; 2008 Jul; 23(7):1602-6. PubMed ID: 18378560
[TBL] [Abstract][Full Text] [Related]
38. Effects of pioglitazone on beta-cell function in metabolic syndrome patients with impaired glucose tolerance.
Jin J; Yu Y; Yu H; Wang C; Zhang X
Diabetes Res Clin Pract; 2006 Dec; 74(3):233-41. PubMed ID: 16764964
[TBL] [Abstract][Full Text] [Related]
39. Metformin versus rosiglitazone in the treatment of polycystic ovary syndrome.
Mitkov M; Pehlivanov B; Terzieva D
Eur J Obstet Gynecol Reprod Biol; 2006 May; 126(1):93-8. PubMed ID: 16360262
[TBL] [Abstract][Full Text] [Related]
40. The association of bone mineral density with insulin resistance in patients with polycystic ovary syndrome.
Noyan V; Yucel A; Sagsoz N
Eur J Obstet Gynecol Reprod Biol; 2004 Aug; 115(2):200-5. PubMed ID: 15262356
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
